Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin
This trial is active, not recruiting.
|Conditions||urinary tract infection, fluoroquinolone, bacteremia|
|Sponsor||University of Pittsburgh|
|Collaborator||Japan Health Sciences Foundation|
|Start date||February 2007|
|End date||December 2016|
|Trial size||1000 participants|
|Trial identifier||NCT00414362, IRB#0611103, no additional IDs|
The information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially Escherichia coli. The current IDSA guideline endorses the use of fluoroquinolones and trimethoprim-sulfamethoxazole as the first line agents. However, over use of this empiric regimen could result in in appropriate treatment of bacteremia.
dead or alive
time frame: end of study
Male or female participants at least 18 years old.
Inclusion Criteria: - Clinical information is collected by chart review of "case" and "control" patients. A "case" patient is defined as follows: - One or more blood cultures are positive for Gram-negative bacteria. - The same organism is recovered in urine culture within a 48-hour period. - The organism is ciprofloxacin resistant. - A "control" patient is defined as follows: - One or more blood cultures are positive for Gram-negative bacteria. - The same organism is recovered in urine culture within a 48-hour period. - The organism is ciprofloxacin susceptible. Exclusion Criteria: - negative culture
|Official title||Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin|
|Principal investigator||Yohei Doi, MD|
|Description||The following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. We will collect information retrospectively.|
Call for more information